Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Clinical Lymphoma Myeloma & LeukemiaOpen Access

Pomalidomide, cyclophosphamide and dexamethasone for relapsed/refractory multiple myeloma; a single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

INIoannis Ntanasis‐StathopoulosPMPanagiotis MalandrakisCFCharalampos Filippatos

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows PCd therapy improved overall response rate and clinical outcomes in relapsed/refractory multiple myeloma patients, suggesting potential benefits in treatment planning.

Key Points

  • The overall response rate (ORR) for patients treated with PCd was 46.7%, indicating moderate efficacy.
  • Patients with high-risk cytogenetics experienced significantly worse progression-free survival (PFS), suggesting the need for tailored treatment strategies.
  • The median progression-free survival was reported at 9.0 months, highlighting challenges in managing this patient population with relapsed/refractory disease.
  • Neutropenia was the most common severe toxicity, emphasizing the importance of monitoring patient safety during treatment.

Cite This Study

Ntanasis‐Stathopoulos et al. (2025) studied this question.

synapsesocial.com/papers/68c24236b210217d647a2b0bhttps://doi.org/10.1016/j.clml.2025.08.003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025
  2. 2Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population2025
  3. 3Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd2025 · 2 citations
  4. 4Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  5. 5Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: An Italian case series2025 · 2 citations